×

Stocks Johnson & Johnson

  • Despite a pull back in the U.S. equity markets last week, the S&P and Nasdaq Composite are having their best September since 1998 so far, while the Dow is on track for its biggest % gain in September since 2007.  Even though September ranks as the worst month historically on average for all three indices, the Nasdaq Composite has traded up 12 sessions out of 19 as of Monday's close while the Dow and S&P have finished up 11 days of 19.

  • Investors are placing their bets on the next M&A deal in biotech. Where should you be looking?

  • The Dow and S&P rallied on Monday, snapping a three-day losing streak, as a string of corporate takeovers fueled optimism that value remained in the market.

  • Stocks snapped a three-day losing streak Monday as investors cheered a wave of merger-and-acquisition activity.

  • How should you put money to work in the wake of this uptick in M&A?

  • Stocks rallied Monday, after a three-day losing streak, as investors cheered a wave of merger-and-acquisition activity.

  • Mergers and acquisitions, rising Japanese yen and the Judaic Day of Atonement: what do they mean for stocks? Art Cashin, director of floor operations at UBS Financial Services, offered CNBC his market insights.

  • Propelled by M&A activity and chatter, U.S. stock futures are up modestly this morning despite a sell-off in Asian markets overnight.

  • Futures swung to indicate a positive open for Wall Street on Monday, riding a wave of merger and acquisition activity and despite stocks in Europe and Asia falling.

  • As we approach another quarter and month end, with just four days to go, the Dow is on track for its best third quarter since 1939, the S&P is on course for its biggest Q3 gains since 1970, and the Nasdaq Composite is having its best Q3 since 1997, based on September 24 closing levels.  Will the markets continue to hold on to gains or sell off by the end of the year?

  • James Hardesty at Hardesty Capital Management and Wayne Kaufman at John Thomas Financial weighed in on where to invest in a low-volume environment and what to watch next week.

  • Twitter

    The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.

  • Charles Bobrinskoy, vice chairman and director of research at Ariel Investments and Marc Harris, co-head of Global Research at RBC Capital Markets shared their insights on where to invest in a low volume environment and what investors should be watching for next week.

  • 3M has soared almost 80 percent since the March market low, and recently hit its 52-week high. Where's the stock headed? Deane Dray, senior diversified industrials analyst at FBR Capital Markets, shared his views on the company.

  • Stocks moved into positive territory Monday afternoon as tech, bank and drug stocks gained and volatility waned.

  • Stocks pared their losses Monday as President Obama's speech on financial reform had little impact on the market.

  • Stocks declined Monday as investors worried about a trade dispute between the US and China and reflected on the one-year anniversary of the Lehman Brothers collapse.

  • One year ago on Sunday September 14, Lehman Brothers was scrambling before declaring bankruptcy later that night and Bank of America announced a deal to acquire Merrill Lynch.  Here is a look at where major indices and stocks look one year later.

  • Qnexa

    Some analysts had been telling clients recently that they thought Vivus' diet drug Qnexa could take the lead in the three-contestant race to get the next prescription diet pill on the market. But they didn't think it would take such a commanding lead.

  • Warren Buffett

    Warren Buffett always says he loves to go to work each day, and the global financial crisis has done nothing to damper that enthusiasm for his job. Buffett tells the New York Times that all the "drama" has made for an "incredibly interesting period in the last year and a half."